NCT04791826 is a NA clinical trial of On-screen electronic alert in Heart Failure, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT04791826?

NCT04791826 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT04791826?

Interventions in NCT04791826: On-screen electronic alert.

What condition does NCT04791826 study?

NCT04791826 studies Heart Failure, Diabetes Mellitus, Type 2.

Is NCT04791826 still recruiting?

NCT04791826 is currently completed. Last updated 6 June 2024.

Last reviewed 2024-06-06 · How we verify

NCT04791826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electronic Alerts for Heart Failure Prevention in Diabetes

Completed NA Last updated 6 June 2024

What this trial tests

NA trial testing On-screen electronic alert in Heart Failure in 1,524 participants. Completed in 7 May 2024.

Timeline

25 March 2021

Primary endpoint
31 July 2022

7 May 2024

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	1,524
Start date	25 March 2021
Primary completion	31 July 2022
Estimated completion	7 May 2024
Sites	1 location across United States

Drugs / interventions tested

On-screen electronic alert

Conditions studied

Heart Failure — all drugs for Heart Failure →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Heart Failure or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 2 diabetes mellitus (T2DM) is an independent risk factor for heart failure (HF) and is associated with significant morbidity and mortality. Recent therapeutic advances in pharmacotherapies, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown to be beneficial in preventing HF among patients with T2DM. However, despite widely available risk prediction and stratification tools and evidence-based practice guidelines, SGLT-2i medications are under-prescribed in the United States. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a clinical decision support (CDS) tool to alert providers and improve HF risk stratification in patients with T2DM.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.
Segar MW, Khan MS, Patel KV, Vaduganathan M, et al · · 2022 · cited 32× · PMID 34730265 · DOI 10.1002/ejhf.2375
Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial.
Segar MW, Patel KV, Keshvani N, Kannan V, et al · · 2025 · cited 1× · PMID 39254082 · DOI 10.1177/19322968241264747

Verify or expand the search:

Other trials of On-screen electronic alert

Trials testing the same drug.

NCT02958943 — Electronic Alerts for Stroke Prevention in Atrial Fibrillation · NA · completed

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04791826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 6 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing